e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Experimental pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension
F. C. Weisel, G. Kwapiszewska, C. Kloepping, M. Roth, H. A. Ghofrani, R. T. Schermuly, W. Seeger, F. Grimminger, N. Weissmann (Giessen, Bad Nauheim, Germany)
Source:
Annual Congress 2010 - Experimental pulmonary hypertension
Session:
Experimental pulmonary hypertension
Session type:
Thematic Poster Session
Number:
1076
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. C. Weisel, G. Kwapiszewska, C. Kloepping, M. Roth, H. A. Ghofrani, R. T. Schermuly, W. Seeger, F. Grimminger, N. Weissmann (Giessen, Bad Nauheim, Germany). Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1076
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 53 (6) 1800965; 10.1183/13993003.00965-2018
Year: 2019
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Vascular remodelling is reversed following BMPR2 modified endothelial progenitor cell therapy in a MCT-induced PAH rat model
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Involvement of FHL1 in vascular remodelling
Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling
Year: 2006
Hypoxia-induced pulmonary artery fibroblast proliferation and migration is prevented by ASK1 inhibition in an in vitro cellular model of pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Endothelial NO and its pathophysiologic regulation
Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease
Year: 2007
Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012
Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 365s
Year: 2005
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats
Source: Eur Respir J 2011; 37: 1104-1118
Year: 2011
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept